Annual report pursuant to Section 13 and 15(d)

INTANGIBLE ASSETS

v3.22.1
INTANGIBLE ASSETS
12 Months Ended
Dec. 31, 2021
INTANGIBLE ASSETS [Abstract]  
INTANGIBLE ASSETS

5.

INTANGIBLE ASSETS

 

Intangible assets at December 31, 2021 and 2020 consist of the following:

 

 

 

December 31, 2021

   

December 31, 2020

 

 

 

Cost

   

Accumulated Amortization

   

Net

   

Cost

   

Accumulated Amortization

   

Net

 

Trademark and other intangible rights related to Nabi-HB

  $ 4,100,046     $ 2,684,554     $ 1,415,492     $ 4,100,046     $ 2,098,833     $ 2,001,213  

Rights to intermediates

    907,421       594,145       313,276       907,421       464,513       442,908  

 

  $ 5,007,467     $ 3,278,699     $ 1,728,768     $ 5,007,467     $ 2,563,346     $ 2,444,121  

   

Under the previous contract manufacturing agreement between ADMA and BPC, intermediate by-products derived from the manufacture of ASCENIV were property of Biotest. As a result of the Biotest Transaction, ADMA obtained the right to these intermediate products, which are being amortized over a period of seven years. The intangible rights to Nabi-HB are also being amortized over a period of seven years.

 

Amortization expense related to the Company’s intangible assets for the years ended December 31, 2021 and 2020 was $0.7 million. Estimated aggregate future aggregate amortization expense is expected to be as follows:

 

2022

  $ 715,352  

2023

    715,352  

2024

    298,064